AstraZeneca, Lunit Partner on AI Cancer Mutation Detection Tool

Seoul, South Korea -  Lunit (328130. KQ) has partnered with AstraZeneca to develop artificial intelligence tools for detecting genetic mutations in lung cancer patients.

The collaboration centers on Lunit's AI-powered SCOPE Genotype Predictor, which analyzes tissue slide images to predict the likelihood of non-small cell lung cancer (NSCLC) harboring specific genetic mutations, including EGFR mutations.

The technology aims to provide faster screening results than traditional genomic testing, allowing doctors to prioritize molecular testing for patients with a higher likelihood of having targetable mutations.

"Tools like this will help to address unmet needs by optimizing diagnostic workflows for NSCLC patients," said Kristina Rodnikova, Head of Global Oncology Diagnostics at AstraZeneca's Oncology Business Unit.

The companies plan to validate the screening tool in real-world settings and explore its deployment for detecting lung cancer driver mutations. They will also investigate additional molecular biomarker predictions based on tissue slide analysis.

The partnership aims to make these AI solutions accessible globally to laboratories and healthcare institutions, though no specific timeline was disclosed.